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Abstract
Background: BRAF, KRAS and PIK3CA mutations are frequently found in sporadic colorectal cancer (CRC). In contrast
to  KRAS  and PIK3CA  mutations,  BRAF mutations are associated with tumours harbouring CpG Island methylation
phenotype (CIMP), MLH1 methylation and microsatellite instability (MSI). We aimed at determine the frequency of KRAS,
BRAF  and  PIK3CA  mutations in the process of colorectal tumourigenesis using a series of colorectal polyps and
carcinomas. In the series of polyps CIMP, MLH1 methylation and MSI were also studied.
Methods: Mutation analyses were performed by PCR/sequencing. Bisulfite treated DNA was used to study CIMP and
MLH1 methylation. MSI was detected by pentaplex PCR and Genescan analysis of quasimonomorphic mononucleotide
repeats. Chi Square test and Fisher's Exact test were used to perform association studies.
Results: KRAS, PIK3CA or BRAF occur in 71% of polyps and were mutually exclusive. KRAS mutations occur in 35% of
polyps. PIK3CA was found in one of the polyps. V600E BRAF mutations occur in 29% of cases, all of them classified as
serrated adenoma. CIMP phenotype occurred in 25% of the polyps and all were mutated for BRAF. MLH1 methylation
was not detected and all the polyps were microsatellite stable. The comparison between the frequency of oncogenic
mutations in polyps and CRC (MSI and MSS) lead us to demonstrate that KRAS and PIK3CA are likely to precede both
types of CRC. BRAF mutations are likely to precede MSI carcinomas since the frequency found in serrated polyps is similar
to what is found in MSI CRC (P = 0.9112), but statistically different from what is found in microsatellite stable (MSS)
tumours (P = 0.0191).
Conclusion:  Our results show that BRAF,  KRAS  and  PIK3CA  mutations occur prior to malignant transformation
demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis. Further, we show
that BRAF mutations occur in association with CIMP phenotype in colorectal serrated polyps and verified that colorectal
serrated polyps and MSI CRC show a similar frequency of BRAF mutations. These results support that BRAF mutations
harbour a mild oncogenic effect in comparison to KRAS and suggest that BRAF mutant colorectal cells need to accumulate
extra epigenetic alterations in order to acquire full transformation and evolve to MSI CRC.
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Background
In microsatellite unstable (MSI) colorectal tumours, both
sporadic and inherited forms, hundreds of thousands of
mutations accumulate within repetitive sequences
throughout the genome [1]. Although genes with repeti-
tive sequences are clear targets in tumours with a defective
mismatch repair system, mutations in non-repetitive
sequences are also found in MSI tumours. An example of
this is the occurrence of activating mutations of KRAS,
PIK3CA and BRAF genes.
Activating mutations of BRAF and KRAS are frequently
found in sporadic colorectal (CRC) cancer. BRAF muta-
tions occur in about 10 to 18% of CRC overall and in 30
to 45% of MSI CRC [2,3], more frequently in tumours
harbouring  MLH1  promoter hypermethylation [3] and
with a CpG island methylation phenotype (CIMP) [4]. In
microsatellite stable (MSS) CRC BRAF mutations are rare
and whenever present are associated with advanced carci-
nomas [5]. KRAS mutations occur in both MSI (in about
20%) [3,6,7] and MSS (in about 35%) subsets of sporadic
CRC [5,6]. Within the MSI subset of CRC KRAS mutations
do not associate with the presence of MLH1  promoter
hypermethylation [3] or with the presence of CIMP [8].
PIK3CA  mutations were identified in various tumour
models [9]. In colorectal tumours, PIK3CA mutations are
present in 14% to 25% of the cases [9,10] and no differ-
ences in frequency and type of PIK3CA mutations were
found between MSI and MSS subsets [10]. Further, when-
ever PIK3CA mutations occur in CRC they can occur in
concomitance with activating KRAS-BRAF  mutations,
both in MSI and MSS tumours [10]. Nothing is known on
the relationship between PIK3CA mutations and CIMP or
MLH1 methylation in colorectal carcinomas.
The aim of the present study was to determine the timing
of occurrence of KRAS, BRAF and PIK3CA mutations in
the process of colorectal tumourigenesis and study the
association of these mutational oncogenic events with
CIMP, MLH1 methylation and MSI phenotype. In order to
achieve our goal we evaluated the frequency and type of
these epi/genetic events in a series of 17 colorectal polyps.
Furthermore, we compared the frequency of KRAS, BRAF
and  PIK3CA  mutations found in polyps with the fre-
quency found in a series of 103 sporadic colorectal
tumours, 50 MSI CRC and 53 MSS CRC, in order to under-
stand the importance of these oncogenic events for the
progression of the various types of colorectal cancer.
In conclusion, our results show that mutations of BRAF,
KRAS  and  PIK3CA  occur in non-malignant lesions of
colorectum demonstrating that these oncogenic altera-
tions are primary genetic events in colorectal carcinogen-
esis. Further, we show that BRAF  mutations occur in
association with CIMP phenotype in colorectal serrated
polyps while KRAS  mutations are found alone. These
results support that BRAF mutations harbour a mild onco-
genic effect in comparison to KRAS and suggest that BRAF
mutant colorectal cells need to accumulate extra epige-
netic alterations in order to acquire full transformation.
Methods
Representative blocks of 17 colorectal polyps and 103
colorectal carcinomas formalin-fixed, paraffin embedded
were retrieved from the Department of Pathology of the
Hospital S. João. This study was a retrospective analysis
and is in compliance with Helsinki declaration http://
www.wma.net/e/policy/b3.htm. The 103 sporadic CRC
were previously classified for microsatellite status, 53 were
MSS and 50 were MSI colorectal carcinomas [10]. The his-
tological classification of the seventeen paraffin embed-
ded colorectal polyps is listed in table 1. None of the
patients included in this study had a positive family his-
tory. DNA from these 17 polyps was extracted using the
Invisorb Spin Tissue Mini Kit (Invitek). BRAF (exon 15)
and KRAS (exon 1) were amplified by PCR and the pres-
ence of mutations was detected by direct sequencing. To
perform methylation studies, DNA extracted from paraf-
fin embedded lesions was submitted to bisulfite treat-
ment. CIMP was determined in 12 cases by methylation
specific PCR (MSP) using the new panel of five markers
described by Weisenberger [4]. The polyps were classified
as CIMP (≥ 3 methylated markers), and CIMP-negative (≤
2 methylated markers). We were able to analyze MLH1
methylation in 7 samples. For that the promoter region of
the gene was amplified using a set of CpG island flanking
primers (sense 5'ttttgtttttattggttggatattt, antisense 5'cct-
tcaaccaatcacctcaatacct) followed by direct sequencing.
Microsatellite instability studies were performed by genes-
can analyses of a PCR amplified panel of five mononucle-
otide markers (NR27, NR24, NR21, Bat25 and Bat26)
using the Multiplex PCR Kit (Qiagen). MSI was consid-
ered when two or more microsatellite markers were
altered. Association studies between the frequency of
KRAS, PIK3CA and BRAF in colorectal polyps and MSI
and MSS CRC were performed using the Chi Square test
and Fisher's Exact test. A P-value ≤ 0.05 was considered to
be statistically significant.
Results
KRAS, PIK3CA, and BRAF mutations occur prior to 
malignant transformation
In our series of colorectal polyps, we found that mutations
in  KRAS,  PIK3CA  or  BRAF  are mutually exclusive and
occur in the majority of these pre-malignant colorectal
lesions. Mutations in KRAS, PIK3CA or BRAF occur in 12
(70.6%) of the 17 colorectal polyps (Table 1).
KRAS mutations were found in 35.3% (6/17) of polyps.
KRAS  mutant polyps showed three different types ofBMC Cancer 2008, 8:255 http://www.biomedcentral.com/1471-2407/8/255
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mutations with the same frequency within the two most
common hotspot codons (12 and 13): G12D (33.3% – 2/
6), G12V (33.3% – 2/6) and G13D (33.3% – 2/6). KRAS
mutations were only found in polyps with some areas
with dysplasia.
In contrast with the high frequency of KRAS mutations
found in our series, PIK3CA mutations were observed in
only one of the polyps analyzed (5.9%) (Table 1). The
PIK3CA mutation found was localized to exon 20 and
affects amino acid 1023 leading to an arginine-glutamine
substitution (R1023Q). This PIK3CA mutation resides in
a hotspot exon for mutations that has been previously
reported in a MSI colorectal tumour [10].
BRAF mutations were found in 29.4% (5/17) of the cases
(Table 1). All BRAF mutations found in our series of pol-
yps corresponded to the hotspot BRAF V600E and all pol-
yps with BRAF  mutations exhibited the serrated
architecture.
BRAF mutations occur in association with CIMP 
phenotype in colorectal polyps
We studied the presence of CIMP phenotype, MLH1 pro-
moter methylation and MSI phenotype and their associa-
tion with the presence of KRAS,  BRAF  and  PIK3CA
mutations in the series of polyps.
Using the Weisenberger [4] panel of CIMP markers three
of 12 polyps analyzed (25%) were classified as CIMP (≥ 3
methylated markers). All of the CIMP polyps were
mutated for BRAF (Table 1). None of the CIMP polyps
harbour KRAS mutations.
The methylation analysis of MLH1 was possible in 7 of the
17 polyps. Two of these 7 polyps were mutated for KRAS,
2 harboured BRAF mutations and 3 were wild-type for
both genes. None of the 7 polyps studied harboured
methylation in the promoter region of MLH1 (Table 1).
Furthermore, we determined the MSI status of all polyps
using the pentaplex set of microsatellite markers [11].
None of them were MSI.
Colorectal serrated polyps and MSI CRC show a similar 
frequency of BRAF mutations
In order to understand the importance of KRAS, PIK3CA
and BRAF mutations for the progression of the various
types of colorectal cancer, we compared the frequency of
these oncogenic events in the series of polyps and in 50
MSI and 53 MSS CRC (Figure 1).
Ten of the 50 (20%) MSI and 21 of the 53 (39.6%) MSS
colorectal carcinomas exhibited KRAS mutations. The fre-
quency of KRAS mutations found in the MSI and MSS
CRC was not statistical different from the frequency found
in colorectal polyps (P = 0.2014 and P = 0.7497, respec-
tively).
The same was observed for PIK3CA mutations. MSI and
MSS colorectal carcinomas harbour PIK3CA in 8 of the 50
(16%) and in 6 of the 53 (11.3%) cases, respectively. The
frequency of mutations found in polyps, although lower
Table 1: Summary of the molecular and histological features of the colorectal polyps analyzed
Molecular Classification Histological classification
Sample KRAS BRAF PIK3CA CIMP MLH1 methylation Microsatellite instability Polyp type Dysplasia
1 G12D - - Negative UnMet MSS MHA Mild
2 G12D - - Negative nd MSS MHA Mild
3 G12V - - nd UnMet MSS MHA Mild
4 G12V - - Negative nd MSS HP -
5 G13D - - Negative nd MSS HP -
6 G13D - - Negative nd MSS MHA Mild
7 - V600E - Positive UnMet MSS SA Mild
8 - V600E - Positive UnMet MSS SA Mild
9 - V600E - Positive nd MSS SA Mild
10 - V600E - Negative nd MSS SA Mild
11 - V600E - nd nd MSS SA Moderate
12 - - R1023Q nd nd MSS MHA Mild
13 - - - Negative UnMet MSS MHA Mild
14 - - - Negative UnMet MSS HP -
15 - - - Negative UnMet MSS MHA Mild
16 - - - nd nd MSS MHA Mild
17 - - - nd nd MSS HP -
UnMet – unmethylated; nd – not determined; MHA – Mixed hyperplastic and adenomatous; HP – Hyperplastic polyp; SA – Serrated adenomaBMC Cancer 2008, 8:255 http://www.biomedcentral.com/1471-2407/8/255
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in comparison to colorectal carcinomas, is not statistically
different from MSI (P = 0.4296 - Fisher's Exact P-Value)
and MSS (P > 0.9999 - Fisher's Exact P-Value) colorectal
carcinomas.
Concerning the frequency of BRAF alterations in colorec-
tal carcinomas, 14 of the 50 (28%) MSI and 4 of the 53
(7.5%) in MSS colorectal tumours show BRAF mutations.
We found that MSI CRC and colorectal serrated polyps
show a similar frequency of BRAF mutations (P = 0.9112).
In contrast, the frequency of BRAF mutations in MSS car-
cinomas and colorectal polyps is significantly different (P
= 0.0191).
Discussion
Distinct types of colorectal polyps represent pre-malig-
nant lesions of the intestinal tract. In our series of colorec-
tal polyps we found the majority (71%) harbour
mutations in KRAS  (35.3%),  PIK3CA  (5.9%) or BRAF
(29.4%) genes. Regarding KRAS mutations we show that
these mutations occur in cases of hyperplasic polyps and
in hyperplastic polyps with some areas of dysplasia in
accordance to the recent reports of Wynter [12] and
O'Brien [13] showing that KRAS mutations occur in pre-
malignant lesions of the colorectum other than pure ade-
nomas. When comparing the frequency of KRAS muta-
tions found in our series of colorectal polyps with those
observed within the MSS and MSI subsets of CRC, the fre-
quency of KRAS mutations found in polyps is not statisti-
cally different from the frequency observed in MSI and
MSS colorectal tumours (Figure 1). Both observations
highlight the role of KRAS activation in the initiation of
the different types of sporadic CRC [12-14] besides its role
in the adenoma-carcinoma multistep pathway of colorec-
tal carcinogenesis [15].
PIK3CA mutations were found in only one of the polyps
(6%) but this frequency is not significantly different from
what is observed in CRC independently of MSI status. The
mutation found in our series of colorectal polyps was pre-
viously described in a colorectal tumour [10] suggesting
that it harbours a pathogenic effect. Further, it is interest-
ing to note that the PIK3CA alteration found in the single
affected polyp is wild-type KRAS  and  BRAF  case. This
result suggests that mutant PIK3CA is likely to be an alter-
native rare genetic event to KRAS and BRAF in pre-malig-
nant lesions of the colon.
The frequency of BRAF  mutations in polyps (30%) is
higher than the frequency observed in overall CRC (17%).
This observation lead us to speculate that a fraction of
BRAF mutant polyps do not progress to carcinoma and
remain as non-malignant colorectal lesions as an end-
point stage. In accordance with this, it was demonstrated
in mice that expression of active BRAF in the lungs lead to
an initial burst of cell proliferation followed by growth
arrest rarely inducing spontaneous progression to adeno-
carcinoma unless mice were deliberately engineered to
lack the TP53 or Ink4a/Arf tumour suppressor genes [16].
This study and our data suggest that BRAF may need to
cooperate with other factors (genetic or epigenetic) to
progress to colorectal carcinoma, as it was previously pro-
posed for human naevi [17,18].
Noteworthy, the frequency of BRAF mutations in colorec-
tal polyps is similar to the frequency observed in MSI CRC
(28%) (P = 0.9112). These data raises the hypothesis that
mutant BRAF triggers a distinct pathway of colorectal car-
cinogenesis leading to the formation of MSI colorectal
tumours different from the adenoma-carcinoma
sequence. Interestingly BRAF mutations occurred only in
polyps with the serrated architecture supporting that
BRAF activation is pivotal in the serrated pathway of CRC
as advanced previously by Jass [19,20] and other authors
[13,14,21,22].
Analyzing the frequency of CIMP in colorectal polyps we
have demonstrated that the results obtained are similar to
what was described in CRC [13,14,20,22] showing that
BRAF mutations are associated with CIMP phenotype in
the initial steps of carcinogenesis before malignant trans-
formation. In contrast, KRAS mutations were only associ-
ated to with low levels of methylation as it was previously
observed in primary colorectal tumours [19,23], demon-
KRAS, PIK3CA and BRAF mutation frequencies between MSI/ MSS CRC and CR polyps Figure 1
KRAS, PIK3CA and BRAF mutation frequencies 
between MSI/MSS CRC and CR polyps. The frequency 
of KRAS, PIK3CA and BRAF mutations in MSI and MSS CRC 
was based on previous results of our group in Velho [10]. In 
brackets is represented the total of cases that were analyzed 
for each gene.BMC Cancer 2008, 8:255 http://www.biomedcentral.com/1471-2407/8/255
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strating that KRAS mutations are associated to mild effects
in the methylation profile during colorectal carcinogene-
sis. These results support that BRAF mutations harbour a
mild oncogenic effect in comparison to KRAS and suggest
BRAF mutant colorectal cells need to accumulate extra
epigenetic alterations in order to acquire full transforma-
tion.
MSI and loss of expression of MLH1 due to promoter
hypermethylation are frequently associated with BRAF
mutation and CIMP in MSI sporadic colorectal tumours
[2-4]. In our series of colorectal polyps we did not
detected MLH1 promoter hypermethylation which is in
agreement with the fact that none of the analyzed polyps
harboured MSI. Our data is in agreement with the results
previously described in serrated adenomas described by
Sawyer [24] demonstrating that BRAF and CIMP precedes
MSI as proposed by the model advanced by O'Brien [14].
The late acquisition of MLH1 methylation leading to the
accumulation of mutations throughout the genome tar-
geting important genes (tumour suppressor genes or
proto-oncogenes) involved in the control of cellular
homeostasis may bridge the transition from a pre-malig-
nant to a malignant lesion.
Conclusion
In conclusion, our results show that mutations of KRAS
and PIK3CA occur in non-malignant lesions of colorec-
tum and the frequency of these mutations is not distinct
in polyps and MSS and MSI CRC demonstrating that these
oncogenic alterations are primary genetic events in the
two subsets of colorectal carcinogenesis. Further, we show
that BRAF mutations occur in association with CIMP phe-
notype in colorectal serrated polyps while KRAS muta-
tions are found alone. Further we show that only MSI CRC
and colorectal serrated polyps harbour similar frequency
of BRAF mutations. These results support that BRAF muta-
tions harbour a mild oncogenic effect in comparison to
KRAS and suggest that BRAF mutant colorectal cells need
to accumulate extra epigenetic alterations in order to
acquire full transformation and evolve to MSI CRC.
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